<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580914</url>
  </required_header>
  <id_info>
    <org_study_id>92567361</org_study_id>
    <nct_id>NCT04580914</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation</brief_title>
  <acronym>NEwTON AF</acronym>
  <official_title>Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NEwTON AF study is a multi-center, global, prospective, single arm study to establish the&#xD;
      safety and effectiveness of the IntellaNav StablePoint Catheter and Force-Sensing System in&#xD;
      subjects with symptomatic, drug refractory, recurrent paroxysmal atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Primary Safety Events at 1-Month Post-Procedure</measure>
    <time_frame>Up to 30 Days</time_frame>
    <description>The primary safety endpoint at 30 days is defined as the safety event-free rate at 1-Month (30 days) post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Treatment Failure at 6-Months Post-Procedure</measure>
    <time_frame>Up to 6 Months</time_frame>
    <description>The primary effectiveness endpoint at 6 months is defined as event-free rate, which will be evaluated at a six-month interim analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Primary Safety Events at 12-Months Post-Procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>The primary safety endpoint at 12 months is defined as the safety event-free rate at 12 months post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from Treatment Failure at 12-Months Post-Procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>The twelve-month effectiveness endpoint is defined as the event-free rate at twelve-month post-procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants that achieved electrical isolation of all pulmonary veins</measure>
    <time_frame>30 Days</time_frame>
    <description>The primary effectiveness endpoint of acute procedural success is defined as the achievement of electrical isolation of all PVs using the IntellaNav StablePoint catheter only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of SAEs and AEs through 12-Months Post-Procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary Safety Endpoint - SAE and AE Rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with New or Increased Dose of AAD</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary Effectiveness Endpoint 1 - New or Increased Dose of AAD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from primary effectiveness failure without a repeat procedure</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary Effectiveness Endpoint 2 - Single Procedure Success defined as freedom from primary effectiveness failure without a repeat procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from documented symptomatic Atrial Fibrillation, Atrial Flutter and Atrial Tachycardia Recurrence</measure>
    <time_frame>12 Months</time_frame>
    <description>Secondary Effectiveness Endpoint 3 - Symptomatic Recurrence: freedom from documented symptomatic AF/AT/AFL recurrence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">299</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment with Ablation Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo treatment with the ablation catheter for the treatment of paroxysmal atrial fibrillation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treatment with IntellaNav StablePoint Ablation Catheter</intervention_name>
    <description>Patients will be treated with an ablation catheter</description>
    <arm_group_label>Treatment with Ablation Catheter</arm_group_label>
    <other_name>IntellaNav StablePoint Catheter System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. History of recurrent symptomatic Paroxysmal Atrial Fibrillation (PAF), defined as&#xD;
             atrial fibrillation (AF) that terminates spontaneously or with intervention (either&#xD;
             procedure or drug therapy) within seven days of onset. Minimum documentation includes&#xD;
             the following:&#xD;
&#xD;
             a physician's note indicating recurrent self-terminating atrial fibrillation (AF)&#xD;
             which includes at least two symptomatic AF episodes in the patient's history within&#xD;
             the last 6 months prior to enrollment, and any electrocardiographically documented AF&#xD;
             episode within 12 months prior to enrollment.&#xD;
&#xD;
          2. Subjects who are eligible for an ablation procedure for PAF according to 2017 HRS&#xD;
             expert consensus statement on catheter ablation of atrial fibrillation;&#xD;
&#xD;
          3. Subjects refractory or intolerant to at least one class I or class III antiarrhythmic&#xD;
             medication or contraindicated to any class I or class III medications;&#xD;
&#xD;
          4. Subjects who are willing and capable of providing informed consent;&#xD;
&#xD;
          5. Subjects who are willing and capable of participating in all testing associated with&#xD;
             this clinical investigation at an approved clinical investigational center;&#xD;
&#xD;
          6. Subjects whose age is 18 years or above, or who are of legal age to give informed&#xD;
             consent specific to state and national law.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with New York Heart Association (NYHA) Class III or IV heart failure &lt; 180&#xD;
             days prior to enrollment&#xD;
&#xD;
          2. Left atrial diameter &gt; 5.0 cm or left atrial volume &gt;50 ml/m² indexed based on the&#xD;
             most recent echocardiography+&#xD;
&#xD;
          3. Left ventricular ejection fraction &lt; 35% based on the most recent echocardiogram +&#xD;
&#xD;
          4. Continuous AF lasting longer than seven (7) days&#xD;
&#xD;
          5. Subjects who have undergone any previous left atrial cardiac ablation (RF, Cryo,&#xD;
             surgical)&#xD;
&#xD;
          6. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible&#xD;
             or non-cardiac cause&#xD;
&#xD;
          7. Subjects who have undergone any cardiac ablation or any surgery within 30 days prior&#xD;
             to enrollment&#xD;
&#xD;
          8. Currently implanted with a pacemaker, ICD, CRT device, or an implanted arrhythmia loop&#xD;
             recorder&#xD;
&#xD;
          9. Active systemic infection&#xD;
&#xD;
         10. Unstable angina or ongoing myocardial ischemia&#xD;
&#xD;
         11. Myocardial Infarction (MI) within 90 days prior to enrollment&#xD;
&#xD;
         12. Evidence of myxoma, left atrial thrombus or intracardiac mural thrombus++&#xD;
&#xD;
         13. Previous cardiac surgery (i.e. ventriculotomy, atriotomy, CABG, PTCA, PCI, coronary&#xD;
             stenting procedures) ≤ 90 days prior to enrollment.&#xD;
&#xD;
         14. Severe valvular disease, including mechanical prosthetic mitral or tricuspid heart&#xD;
             valves (patients with successful mitral valve repair allowed - annular ring&#xD;
             constitutes repair);&#xD;
&#xD;
         15. Any prior history of documented cerebral infarct, TIA or systemic embolism [excluding&#xD;
             a post-operative deep vein thrombosis (DVT)] &lt;180 days prior to enrollment&#xD;
&#xD;
         16. Moderate or severe mitral stenosis (severity assessed on the most recent TTE ≤180 days&#xD;
             prior to enrollment. Defined as pulmonary artery systolic pressure &gt;30 mmHg)&#xD;
&#xD;
         17. Presence of left atrial appendage closure device&#xD;
&#xD;
         18. Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder&#xD;
&#xD;
         19. Subjects who, in the judgment of the investigator, have a life expectancy of less than&#xD;
             two (2) years&#xD;
&#xD;
         20. Women of childbearing potential who are, or plan to become, pregnant during the time&#xD;
             of the study (method of assessment upon investigator's discretion)&#xD;
&#xD;
         21. Amiodarone use within 60 days prior to enrollment&#xD;
&#xD;
         22. Any carotid stenting or endarterectomy&#xD;
&#xD;
         23. Stage 3B renal disease or higher (estimated glomerular filtration rate, eGFR &lt;45&#xD;
             mL/min)&#xD;
&#xD;
         24. Known coagulopathy disorder (e.g. von Willebrand's disease, hemophilia)&#xD;
&#xD;
         25. Any known contraindication to an AF ablation&#xD;
&#xD;
         26. Any known contraindication for anticoagulation (e.g. patients unable to receive&#xD;
             heparin or an acceptable alternative to achieve adequate anticoagulation)&#xD;
&#xD;
         27. Vena cava embolic protection filter devices and/or known femoral thrombus that&#xD;
             prevents catheter insertion from the femoral approach&#xD;
&#xD;
         28. Known sensitivity to contrast media (if needed during the procedure) that cannot be&#xD;
             controlled with pre-medication&#xD;
&#xD;
         29. Rheumatic Heart Disease&#xD;
&#xD;
         30. Presence of intramural thrombus, tumor or other abnormality that precludes vascular&#xD;
             access, or manipulation of the catheter&#xD;
&#xD;
         31. Subjects unable or unwilling to complete follow-up visits and examinations for the&#xD;
             duration of the clinical study&#xD;
&#xD;
         32. Subjects who are currently enrolled in another investigational study or registry that&#xD;
             would directly interfere with the current study, except when the subject is&#xD;
             participating in a mandatory governmental registry, or a purely observational registry&#xD;
             with no associated treatments; each instance must be brought to the attention of the&#xD;
             sponsor to determine eligibility.&#xD;
&#xD;
               -  LVEF and LA diameters obtained ≤180 days prior to enrollment will be acceptable,&#xD;
                  unless a cardiac event has occurred (e.g. MI) between the date of the exam and&#xD;
                  the enrollment date. In this case, a new echocardiogram (trans-thoracic or&#xD;
                  trans-esophageal, or intracardiac echo) must be performed to confirm eligibility&#xD;
                  prior to performing ablation. If no recent (≤180 days prior to enrollment)&#xD;
                  echocardiogram is available at the time of the enrollment, a new echocardiogram&#xD;
                  must be performed either prior to enrolling the patient into the study or&#xD;
                  post-consent to confirm patient's eligibility prior to performing the ablation.&#xD;
                  For TTE, LA anteroposterior diameter measured by M-mode from the parasternal&#xD;
                  long-axis view will be used. If both LA diameter and volume are available and at&#xD;
                  least one of them meets the exclusion criteria, the subject is considered&#xD;
                  ineligible for the study.&#xD;
&#xD;
                    -  The absence of thrombus must be confirmed by means of a trans-esophageal&#xD;
                       echocardiogram (TEE) within 48 hours prior to the procedure or Intracardiac&#xD;
                       Echography (ICE) during the procedure in subjects not adequately&#xD;
                       anticoagulated per Section 10.4.2. If a thrombus is observed, the subject no&#xD;
                       longer meets eligibility criteria and should be considered &quot;Consent&#xD;
                       Ineligible&quot;.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rami Guirguis, MS</last_name>
    <phone>919-374-3388</phone>
    <email>rami.guirguis@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas Boothby, MS</last_name>
    <phone>586-709-9589</phone>
    <email>thomas.boothby2@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arrhythmia Research Group</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Rubino</last_name>
      <phone>870-935-6729</phone>
      <email>krubino@dnairresearch.com</email>
    </contact>
    <investigator>
      <last_name>Devi Nair</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Blackburn</last_name>
      <phone>808-691-8766</phone>
      <email>bblackburn@queens.org</email>
    </contact>
    <investigator>
      <last_name>David Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lukes Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon LaMott</last_name>
      <phone>208-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Bainter</last_name>
      <phone>217492910029142</phone>
      <email>lbainter@prairieresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Issa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Elliott</last_name>
      <phone>319-384-1628</phone>
      <email>trisha-elliott@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Troy Rhodes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Medical Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Young</last_name>
      <phone>515-633-3841</phone>
      <email>jyoung@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Jason Meyers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartik Munshi</last_name>
      <phone>405-608-1286</phone>
      <email>kmunshi@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Madhu Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwyndolyn Middleton</last_name>
      <phone>859-260-4445</phone>
      <email>gmiddlet@bhsi.com</email>
    </contact>
    <investigator>
      <last_name>Johan Aasbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sangeeta Lathkar-Pradhan</last_name>
      <phone>734-358-3704</phone>
      <email>slathkar@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Frank Pelosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Moritz</last_name>
      <phone>603-665-2444</phone>
      <email>lori.moritz@cmc-nh.org</email>
    </contact>
    <investigator>
      <last_name>Jinu John</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Shannon</last_name>
      <email>bshannon@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Chinitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Mueller</last_name>
      <phone>212-746-4617</phone>
      <email>asm4007@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Jim Cheung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Soots</last_name>
      <phone>336-716-2006</phone>
      <email>ssoots@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Whalen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethesda North Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Voorhorst</last_name>
      <phone>513-862-2877</phone>
      <email>anne_voorhorst@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Marshall Winner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Spaller</last_name>
      <phone>216-444-8774</phone>
      <email>spallel@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Callahan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Medical Specialists</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Henry</last_name>
      <phone>610-525-1202</phone>
      <email>ahenry@bmmsa.com</email>
    </contact>
    <investigator>
      <last_name>Sheetal Chandhok</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Meisch</last_name>
      <phone>615-343-4983</phone>
      <email>carol.meisch@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Gregory Michaud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orion Medical</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Morrow</last_name>
      <phone>713-943-2800</phone>
      <email>cherie.morrow@orionmedical.net</email>
    </contact>
    <investigator>
      <last_name>Karan Bhalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Trinity Mother Frances Health System</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Baker</last_name>
      <phone>903-606-3536</phone>
      <email>amanda.baker3@christushealth.org</email>
    </contact>
    <investigator>
      <last_name>Stanislav Weiner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chippenham and Johnston-Willis Hospital (CJW)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Burton</last_name>
      <phone>804-852-2747</phone>
      <email>stephanie.burton@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Guru Mohanty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouw Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steve Aerts</last_name>
      <phone>3252724168</phone>
      <email>steve.aerts@olvz-aalst.be</email>
    </contact>
    <investigator>
      <last_name>Tom De Potter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de Cardiologie et de Pneumologie de Quebec</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine Cote</last_name>
      <email>marie-christine.cote@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Jean François Sarrazin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Centro San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Bosica</last_name>
      <phone>393495486321</phone>
      <email>bosica.francesco@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Manuela Cireddu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>StablePoint</keyword>
  <keyword>Paroxysmal Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

